NCT05985330View on ClinicalTrials.gov

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
OTHER

Measurement of FeNO

Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy

Trial Locations (1)

21000

RECRUITING

Chu Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER